Clinical Trial Update: Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039) [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of Gefapixant (MK-7264) in participants with obstructive sleep apnea has completed and results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obstructive Sleep Apnea

Drugs mentioned

• Gefapixant (MK-7264) (Gefapixant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Obstructive Sleep Apnea (OSA) | Phase 1 | Status: COMPLETED | Results posted: 2020-11-19